Biotech
-
Opinion
What would you fix with a ‘magic wand’? Pharma leaders chime in about clinical trials
How life science execs would transform clinical trials with a little hocus pocus.
By PharmaVoice staff • March 24, 2023 -
Everyone says they’re patient-centric, but have they really walked the walk?
Life science leaders provide practical tips on how to create a sustainable patient-focused culture.
By Karissa Waddick • March 23, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
Podcast
Woman of the Week: RIGImmune’s Susan Sobolov
RIGImmune’s president is setting her sights on an off-the-shelf viral vaccine.
By Taren Grom • March 22, 2023 -
Making the leap from the lab to the boardroom
Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.
By Alexandra Pecci • March 21, 2023 -
SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape
Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.
By Michael Gibney • March 21, 2023 -
Biotech Spotlight
This biotech’s ‘Microsoft’ approach could change how we see gene therapy
The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.
By Karissa Waddick • March 20, 2023 -
‘The Last of Us’ might be fiction, but fungi are a looming threat
Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.
By Kelly Bilodeau • March 20, 2023 -
A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize
Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.
By Taren Grom • March 17, 2023 -
Making Moves
In the fallout from Aduhelm, Biogen’s leadership shakeup continues
The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.
By Karissa Waddick • March 16, 2023 -
Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back
A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.
By Michael Gibney • March 16, 2023 -
Podcast
Woman of the Week: Novartis Gene Therapies’ Chris Fox
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...
By Taren Grom • March 15, 2023 -
Profile
The power of connections for a startup CEO
Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.
By Alexandra Pecci • March 14, 2023 -
Profile
A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch
To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.
By Michael Gibney • March 14, 2023 -
Biden doubles down on drug pricing in 2024 budget — but boosts R&D
The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.
By Karissa Waddick • March 13, 2023 -
Q&A
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
By Kelly Bilodeau • March 13, 2023 -
Q&A // Biotech Spotlight
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
By Karissa Waddick • March 9, 2023 -
Podcast
Woman of the Week: Lucy Therapeutics’ Amy Ripka
How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.
By Taren Grom • March 8, 2023 -
Targeting the new ‘Golden Girls’
With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.
By Taren Grom • March 8, 2023 -
3 keys to good storytelling in pharma
The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.
By Alexandra Pecci • March 7, 2023 -
Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?
The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?
By Michael Gibney • March 7, 2023 -
FDA ups generics and biosimilar approvals for a shot at lower drug costs
As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022.
By Karissa Waddick • March 6, 2023 -
Why layoffs are not the answer to biopharma’s troubled market
As companies look to cut costs, an EY analyst urges them to consider not cutting staff.
By Kelly Bilodeau • March 6, 2023 -
PharmaVoice 100 honorees: Where are they now?
How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles.
By Taren Grom , Karissa Waddick • March 3, 2023 -
Q&A // Biotech Spotlight
Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
By Taren Grom • March 2, 2023 -
Q&A // First 90 Days
The ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
By Michael Gibney • March 2, 2023